Cellectar Biosciences, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Mailing Address 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Phone (608) 441-8120
Fiscal Year End 1231
EIN 043321804
Financial Overview
FY2024
-$42.77M
Net Income
$25.47M
Total Assets
$25.85M
Total Liabilities
$14.29M
Stockholders' Equity
$-1.22
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| S-1 IPO registration statement | October 20, 2025 | View on SEC |
| 8-K Current report of material events | October 10, 2025 | View on SEC |
| 8-K Current report of material events | October 6, 2025 | View on SEC |
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.